A shorter course of radiation with three drugs for newly diagnosed lymphoma that starts in the brain or spinal cord
Original title: Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the treatment is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a short radiation course plus three drugs can help people just diagnosed with a lymphoma that starts in the brain or spinal cord.
Who this trial is for. This trial is for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma. That is a lymphoma that starts in the brain or spinal cord. It tests a shorter course of radiation given together with three drugs: GM-CSF, pomalidomide, and glofitamab.
Where it stands. There are no results yet. The trial is measuring how well this combination works and how safe it is. Those answers are not in yet. Nothing here tells us whether it helps.
What this means, and what it doesn't
What it could mean: For now this is a question being asked, not an answer. If this diagnosis fits you or someone you care for, you could ask your care team about it. They can tell you if it makes sense to look into. Whether anyone can join is up to the trial team.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Being in one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.